Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

Melinda S. Merchant, Matthew Wright, Kristin Baird, Leonard H. Wexler, Carlos Rodriguez-Galindo, Donna Bernstein, Cindy Delbrook, Maya Lodish, Rachel Bishop, Jedd D. Wolchok, Howard Streicher, and Crystal L. Mackall

Abstract

Purpose: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol.

Experimental Design: This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab administered to subjects ≤21 years old with recurrent or progressive solid tumors. Dose escalation cohorts received 1, 3, 5, or 10 mg/m² intravenously every 3 weeks in a 3 + 3 design. Response was assessed after 6 weeks and 12 weeks, and then every 3 months. Treatment was continued until disease progression or unacceptable toxicity.

Results: Thirty-three patients received 72 doses of ipilimumab. Patients enrolled had melanoma (n = 12), sarcoma (n = 17), or other refractory solid tumors (n = 4). Immune-related adverse events included pancreatitis, pneumonitis, colitis, endocrinopathies, and transaminitis with dose-limiting toxicities observed at 5 and 10 mg/kg dose levels. Pharmacokinetics revealed a half-life of 8 to 15 days. At day 21, subjects had increased levels of cycling T cells, but no change in regulatory T-cell populations. Six subjects had confirmed stable disease for 4 to 10 cycles (melanoma, osteosarcoma, clear cell sarcoma, and synovial sarcoma).

Conclusions: Ipilimumab was safely administered to pediatric patients using management algorithms for immune-related toxicities. The spectrum of immune-related adverse events is similar to those described in adults; however, many of the pediatric toxicities were evident after a single dose. Although no objective tumor regressions were observed with ipilimumab as a single agent, subjects with immune-related toxicities had an increased overall survival compared with those who showed no evidence of breaking tolerance. Clin Cancer Res; 22(6): 1364–70. ©2015 AACR.

Introduction

During the course of tumor growth, T cells can recognize tumor-associated antigens and mediate anticancer immune responses. However, inhibitory signals delivered via immune checkpoints such cytotoxic T lymphocyte antigen 4 (CTLA-4) or programmed death receptor 1 (PD1) can dampen naturally acquired antitumor immune responses (reviewed in ref. 1). Ipilimumab is a fully human monoclonal antibody that binds CTLA-4 and blocks its interaction with B7-1 and B7-2 (CD80 and CD86), thus inhibiting this immune checkpoint (2–4). In the presence of ipilimumab, B7-1 preferentially binds CD28, which provides costimulation that activates T cells (3). The overall response rates reported for ipilimumab monotherapy in metastatic melanoma range from 4% to 15% (5–9). On the basis of pivotal phase III studies showing increased survival, ipilimumab was approved for the treatment of metastatic melanoma at 3 mg/kg (10). Several trials in adult patients with melanoma showed safety and potential increased efficacy with higher doses up to 10 mg/kg (5, 11, 12). Clinical responses following ipilimumab are often durable as evidenced by long-term follow-up of patients from single institution trials (13) and review of phase II clinical trials of ipilimumab revealed 4-year survival rates of 37.7%–49.5% in treatment-naïve patients who received ipilimumab at 10 mg/kg (14). Ipilimumab-mediated inhibition of CTLA4 signaling can also result in tissue-specific inflammation, as a result of expansion or activation of autoreactive cell populations, which leads to immune-mediated side effects (15–17). The most commonly reported immune-related adverse events in patients treated with ipilimumab are rash, colitis, transaminitis, and endocrinopathies (18). Prior to this study, it was unknown whether CTLA-4 blockade would have similar immune-mediated effects in children.

Pediatric melanoma is a rare and aggressive malignancy (19). Early-stage disease can be surgically resected with long-term remissions; however, unresectable stage III or IV metastatic disease in the pediatric patient has been difficult to treat and lacks curative options (20). Like malignant melanoma occurring in adults, T-cell infiltrates are often found within the tumor, thus inhibition of the immune checkpoint is of interest as a potential
treatment modality. Many other pediatric solid tumors including neuroblastoma, osteosarcoma, rhabdomyosarcoma, and synovial sarcoma have preclinical or clinical evidence of an immune-mediated antitumor response (21–25). This phase I study of ipilimumab was open to patients ages 1–21 years with solid tumors, excluding primary brain tumors. Primary objectives were to determine safety and pharmacokinetics of the drug as well as to define the toxicity profile of this first immune checkpoint inhibitor to be given to children.

Methods

The study population included patients ages 2–21 years old with recurrent or refractory solid tumors. Patients must have completed irradiation or chemotherapy at least 3 weeks prior to enrollment, and biologic therapy at least 1 week prior to treatment. Other inclusion criteria included adequate performance and end organ function, specifically Kamofsky or Lansky score > 50%, hemoglobin concentration > 8 g/dL, absolute granulocyte count > 1,000/mm³, platelet count > 75,000/mm³, aspartate transaminase (AST), and alanine transaminase (ALT) ≤ 2.5-fold the upper limit of normal (ULN), as well as bilirubin and serum creatinine within normal limits. Patients with primary brain malignancies were excluded from the trial but asymptomatic patients with subcentimeter or treated brain metastases were eligible for enrollment.

Study design and treatment

NCI 08-C-0007 (NCT01445379) opened as a single center phase I study at the NIH Clinical Center (Bethesda, MD) and was subsequently expanded to include enrollment at Memorial Sloan-Kettering Cancer Center (New York, NY) and Dana-Farber Cancer Institute (Boston, MA). Designed to test the safety and pharmacokinetics up to 10 mg/kg, the dose escalation portion of the trial enrolled patients in a 3+3 fashion followed by an expansion cohort in two age groups (1–11 and 12–21 years old) for further safety and pharmacokinetic evaluation. Ipilimumab was supplied as a sterile, single use solution in PBS and infused intravenously over 90 minutes using a DEHP and latex-free intravenous administration set with a Braun 1.2 μm in-line filter. Induction therapy comprised 4 cycles of ipilimumab intravenously every 3 weeks. If there was no evidence of progressive disease or dose-limiting toxicity (DLT), maintenance therapy was initiated 3 weeks after induction with infusions of the same dose every 12 weeks.

DLTs

Toxicity was graded according to the NCI Common Toxicity Criteria (CTCAE v3.1). The highest tolerated dose was defined as the maximum dose of ipilimumab administered at which no more than 1 of 6 patients experienced a DLT.

Pharmacokinetics

This trial used the same pharmacokinetic assay method as adult trials (26). Blood samples (5 mL) were collected from a site other than the infusion line for determination of serum ipilimumab concentrations at completion of infusion (day 1) and also on days 2, 4, 8, 15, and 21. Predose samples were obtained prior to cycle 2, cycle 4, and prior to each cycle of maintenance. Blood was processed to obtain serum and aliquots were frozen at −80°C until assayed. Samples were analyzed for ipilimumab concentration and immunogenicity by qualified ELISA as previously described (26). Individual pharmacokinetic [C_{min}, C_{max}, CL, AUC (0–T), AUC (0–21), t_{half}, t_{max}, Vss] and immunogenicity assessments were analyzed.

Evaluation of clinical activity

Baseline imaging was obtained within 14 days prior to the first ipilimumab dose, at 6 weeks and 12 weeks during induction and then every 12 weeks until withdrawal from the study. Imaging for response was appropriate for disease and response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines with modification to allow continued dosing of ipilimumab for up to 50% increase in size of target lesions.

Flow cytometry

Whole blood was obtained to assess immune cell subsets at baseline, precycle 2 and precycle 3. Peripheral blood mononuclear cells were isolated and stained for CD3, CD4, CD8, HLA-DR, foxP3, CD19, CD20, and Ki67 in a CLIA-certified clinical laboratory.

Results

Patient characteristics

A total of 33 patients aged 28 months to 21 years were enrolled in this multicenter trial. Thirty-one patients were fully evaluable for toxicity during the first two cycles of induction therapy. Two patients expired from rapidly progressive disease within 6 weeks of the initial dose of ipilimumab and were replaced for dose escalation, leaving 31 patients that were fully evaluable for toxicity. Twelve patients had unresectable stage I/IIc or stage IV melanoma (Table 1). A heterogeneous group of patients with progressive or refractory sarcoma was also enrolled including osteosarcoma (n = 8), synovial sarcoma (n = 2), clear cell sarcoma (n = 2; also referred to as melanoma of soft parts), rhabdomyosarcoma (n = 2), pleomorphic sarcoma (n = 1), clear cell sarcoma of the kidney (n = 1), and undifferentiated sarcoma (n = 1). Three patients with renal or bladder carcinomas and one patient with neuroblastoma were also treated. Patients without other curative standard therapies were eligible, and the majority had received at least two lines of therapy for relapsed or refractory disease. Of the
patients with melanoma, six had previous biologic therapy with high dose IL2 and/or IFNγ. Two patients with synovial sarcoma had previously received adoptive T-cell therapy. Three patients with melanoma went on to receive adoptive therapy with tumor-infiltrating T cells (TIL) following ipilimumab, but none had received TIL therapy prior to enrolling on this study.

**Dose escalation**

The first two dose levels (1 and 3 mg/kg) accrued 3 patients each without any DLT. One subject at 3 mg/kg dose level had a transient grade 2 transaminitis but no other subjects in these first two dose levels had an immune-related adverse event (irAE) ≥grade 2. At 5 mg/kg, one patient with melanoma developed pancreatitis requiring hospitalization and steroid therapy following a single dose of ipilimumab. Because of this DLT, the dose level was expanded to include 6 evaluable patients. No further DLTs occurred at the 5 mg/kg dose level during the safety evaluation period; however, several irAEs were observed but not considered DLTs due to their onset beyond the first two cycles (Table 2). The maximum dose tested was 10 mg/kg, the highest dose being explored in adult studies. Two evaluable patients developed DLT at this dose level. A child with neuroblastoma developed grade 3 transaminitis following the first dose and a child with melanoma developed grade 3 transaminitis following the second dose of ipilimumab. Both DLTs were in children <12 years old, while 3 adolescent patients in the cohort tolerated the 10 mg/kg without toxicity. Following these DLTs, the 10 mg/kg dose level expansion was continued for adolescent patients ages 12–21 years old while an expanded cohort of 6 children <12 years was studied at 5 mg/kg.

Overall, 18 (55%) of subjects developed any grade irAE and 9 (27%) developed grade 3 or 4 irAE with gastrointestinal and liver toxicities being most common. The incidence of irAEs is within the range observed on adult studies, except for skin manifestations, which occurred at a lower frequency in pediatric and adolescent patients (Table 3). Nine subjects developed irAE after just one dose of ipilimumab. Following management guidelines and early intervention recommendations, there were no fatal irAEs observed in the subjects on this trial. There were no ophthalmologic inflammatory changes identified on evaluation each cycle.

**Toxicity in adolescent patients ages 12–21 years old**

Nine adolescents were treated at the 10 mg/kg dose level. Two of nine subjects had grade 3 irAE (colitis and vomiting in one patient, pleural effusion and pneumonitis in a second patient). The only grade 3/4 nonimmune-related adverse events occurred at 10 mg/kg dose level with one subject developing grade 4 creatine kinase elevation, uric academia, and grade 3 neutropenia that were possibly related to ipilimumab. Two other subjects exhibited grade 1 or 2 toxicities that were likely related to drug administration including myalgias and autoimmune thyroiditis.

Outside of the DLT evaluation period, three adolescent patients had clinically significant irAE. After 4 doses of

<table>
<thead>
<tr>
<th>Table 2. Treatment with ipilimumab by dose level and associated immune-related toxicities</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Immune-Related Toxicities &gt; Grade 2 (week of onset)*</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Patients with Confirmed stable Disease &gt; 6 wks (# cycles received)</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

*Text in bold represent toxicity events that qualified as DLTs.
ipilimumab at 5 mg/kg, a subject with renal cell carcinoma developed hypophysitis, heralded by severe headache, vision changes, and diabetes insipidus without clinical adrenal crisis. Hypophysitis was confirmed by MRI and required steroids for resolution of symptoms. The patient was able to taper off steroids approximately one month later but remained with panhypopituitarism that required hormone replacement (Fig. 1A). One subject with clear cell sarcoma received ipilimumab at 5 mg/kg and developed colitis during week 12 that initially responded to steroids. Approximately 4 weeks into a steroid taper, the patient presented with a colon perforation requiring surgical intervention. An adolescent with osteosarcoma developed grade 3 colitis two weeks into maintenance therapy with 10 mg/kg. The colitis was not sufficiently controlled with corticosteroids and required infliximab for resolution. In each of these cases, the malignancy had been stable prior to development of late DLT but no further ipilimumab was administered.

Toxicity in young child cohort (2–12 years old)
A total of 11 subjects younger than 12 years old were treated on this phase I study. Six patients received drug at 5 mg/kg, which was determined to be the MTD for children 2–12 years old. One patient with a background of severe allergic reactions had an anaphylactic reaction after receiving approximately 4 mL of the first infusion. Ipilimumab was stopped and steroids were given. The patient was removed from study, but tolerated subsequent doses of ipilimumab with steroid pretreatment off study. The remaining five children <12 years of age tolerated ipilimumab 5 mg/kg without any toxicities. During the dose escalation phase, two children <12 years developed immune-related DLT toxicity at 10 mg/kg. One patient with neuroblastoma developed grade 3 colitis on day 8 of treatment and was found to have concurrent norovirus. Of note, this patient had normalization of urine catecholamines following this single dose of ipilimumab and stable disease for 2 months until starting other neuroblastoma-directed therapy. The second patient had a grade 3 transaminitis that resolved within 3 weeks without steroid treatment.

Pharmacokinetics and immunogenicity
Pharmacokinetics are summarized in Table 4. The serum half-life of ipilimumab ranged from 8 to 15 days with a mean that is lower than the 15-day mean half-life identified in the phase I/II study of ipilimumab in adults with melanoma (26). There were no significant differences found between pharmacokinetic values for young children and adolescents or young adults on this study. Toxities did not appear to be related to changes in clearance. Mean t\text{max} occurred between 1.58 and 2.44 hours and 1.56 and 1.93 hours post dose for all dosages for <12 years old and >12 years old, respectively. The serum half-life increased slightly with increasing dose levels. No immunogenicity against ipilimumab developed on study.

Evaluation of clinical activity
A total of four patients had confirmed stable disease and two patients had unconfirmed stable disease. There were no complete responses or partial responses by standard RECIST criteria. One patient with a background of severe allergic reactions had an anaphylactic reaction after receiving approximately 4 mL of the first infusion. Ipilimumab was stopped and steroids were given. The patient was removed from study, but tolerated subsequent doses of ipilimumab with steroid pretreatment off study. The remaining five children <12 years of age tolerated ipilimumab 5 mg/kg without any toxicities. During the dose escalation phase, two children <12 years developed immune-related DLT toxicity at 10 mg/kg. One patient with neuroblastoma developed grade 3 colitis on day 8 of treatment and was found to have concurrent norovirus. Of note, this patient had normalization of urine catecholamines following this single dose of ipilimumab and stable disease for 2 months until starting other neuroblastoma-directed therapy. The second patient had a grade 3 transaminitis that resolved within 3 weeks without steroid treatment.

Toxicities attributable to ipilimumab at all dose levels

<table>
<thead>
<tr>
<th></th>
<th>All grades</th>
<th>Grades 3/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients with irAE</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>All grades</td>
<td>35%</td>
<td>27%</td>
</tr>
<tr>
<td>Colitis/diarrhea</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Rash</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Transaminitis</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Endocrinopathies</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Other irAE</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>&gt;1 irAE</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>

Figure 1.
Clinical findings. A, hypophysitis developed in one adolescent with renal cell carcinoma on trial, heralded by vision changes, headache, and polyuria on cycle 4 day 8. MRI revealed pituitary enlargement that resolved within 2 weeks of corticosteroid treatment (cycle 4 day 19). B, best overall response in an adolescent with unresectable scalp melanoma with visible improvement and 30% decrease in size of this target mass. C, despite lack of complete or partial responses, overall survival in patients with grade 2 or greater irAEs was increased compared with overall survival in patients who only had grade 1 irAE or did not have any irAE.

Table 3. Toxicities attributable to ipilimumab at all dose levels

<table>
<thead>
<tr>
<th>Toxicity</th>
<th>All grades</th>
<th>Grades 3/4</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients with irAE</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>Colitis/diarrhea</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Rash</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Transaminitis</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Endocrinopathies</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Other irAE</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>&gt;1 irAE</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
The fold increase in immune toxicities (Fig. 1C).

We observed an increased overall survival been decreasing during maintenance dosing, increased during reinduction therapy. We observed an increased overall survival in patients who developed grade 2 or greater immune-related adverse events compared with patients who did not have any immune toxicities (Fig. 1C).

Immunomodulatory activity

Significantly increased numbers of circulating cycling (Ki67+) and activated (HLA-DR+) CD3 T cells were identified in patients after one or two cycles of ipilimumab (Fig. 2). The fold increase in activated CD3+ cells was mainly due to activated CD4+ T cells as CD8+ T cells did not significantly increase in number following ipilimumab administration (Fig. 2A and Supplementary Fig. S1). The increase in activated CD4+ HLA-DR+ T cells did not correlate with development of an irAE (Fig. 2B). While increases were observed in cycling T cells (Fig. 2C) there was no increase in absolute numbers of FoxP3+ regulatory T cells that was identified in any subject compared with baseline (Fig. 2D). There was no difference in immune activation when comparing patients with melanoma to sarcoma or when comparing adolescents to younger age children.

Study subjects underwent baseline analysis of endocrine function including TSH, T4, GH, and ACTH and followed longitudinally on study. Two patients developed increasing levels of antithyroglobulin antibodies following administration of ipilimumab. One patient had low-level antithyroglobulin antibodies at baseline without clinical or laboratory manifestations. In both cases, the patients had elevated TSH on study but normal thyroid hormone levels.

Discussion

In this pediatric phase I trial, ipilimumab was tolerated with similar toxicities and pharmacokinetics as reported in adult studies. No grade 2 or higher immune-related toxicities were identified at doses of 3 mg/kg or less, thus demonstrating that pediatric patients tolerate ipilimumab administration at the FDA-approved dose of 3 mg/kg. Because early studies suggested a dose-related response in adult trials (5, 13, 14), dose escalation to 10 mg/kg was undertaken in this pediatric study. We observed an increase in toxicities at 5 and 10 mg/kg, with all grade 3 or 4 irAE occurring in these higher dose levels. Although an increased rate of irAE observed in children <12 years at the 10 mg/kg dose level resulted in expansion of separate cohorts for children less than or greater than 12 years of age, we cannot conclude from this study that the toxicity of ipilimumab varies with age. Importantly, however, at higher doses, ipilimumab clearly induced a break in immune tolerance, which was often seen early in induction, with many of immune-related events occurring in the first 6 weeks. It is difficult to state an exact recommended phase II dose because the approved dose is lower than the maximum tolerated dose for the pediatric age groups in this trial.

The lack of objective responses in this trial could be due to the small sample size in this phase I trial. With no objective response rate of 13% across a large 855 patient expanded access study of adults with metastatic melanoma, we could statistically have missed any active signal in this relatively small phase I study with only 12 subjects with melanoma (9). Overall survival was not a primary objective in this nonrandomized trial and there are few reports of metastatic pediatric melanoma to provide a historical survival comparison, so we are unable to say whether ipilimumab contributed to any meaningful increase in overall survival in melanoma patients treated on this study. Stabilization of disease was observed in several sarcomas, including clear cell sarcoma and osteosarcoma consistent with preclinical studies suggesting a role for T cells in control of osteosarcoma. Interestingly, the overall survival appears to have been better in patients who developed irAE compared with those who did not have any irAE suggesting a possible common mechanism of activity in this heterogeneous group of tumors (Fig. 1).

Disease-related factors could contribute to the absence of clinical activity observed. The majority of patients on this trial had large tumor burden, which could have a negative impact on T-cell–mediated cytotoxicity. Antitumor activity following checkpoint inhibition also relies on a recognizable antigen and the presence of already activated T cells that can recognize and kill the tumor. Melanomas in adults have multiple mutations that may be serve as neoantigens for T-cell response (27), and recent data suggest that mutated proteins may be important for immune responses to nonmelanoma tumors (28, 29). Pediatric tumors typically have low levels of tumor-associated mutations (30, 31), and could prove to be less immunogenic overall. Furthermore, the microenvironment of the sarcomas and other pediatric tumors

<table>
<thead>
<tr>
<th>Pharmacokinetic parameters</th>
<th>1 mg/kg (n = 1)</th>
<th>3 mg/kg (n = 2)</th>
<th>5 mg/kg (n = 5)</th>
<th>10 mg/kg (n = 4)</th>
<th>1 mg/kg (n = 2)</th>
<th>3 mg/kg (n = 1)</th>
<th>5 mg/kg (n = 8)</th>
<th>10 mg/kg (n = 9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (µg/mL)</td>
<td>17.30 (N/A)</td>
<td>51.86 (17.40)</td>
<td>93.35 (13.43)</td>
<td>193.4 (16.93)</td>
<td>20.26 (12.38)</td>
<td>81.50 N/A</td>
<td>90.56 (25.15)</td>
<td>203.3 (22.21)</td>
</tr>
<tr>
<td>AUC0–21 (µg·h/mL)</td>
<td>255.4 (N/A)</td>
<td>572.31 (16.41)</td>
<td>1637.5 (19.84)</td>
<td>3703.1 (17.54)</td>
<td>1566.9 (347.60)</td>
<td>8481.4 (N/A)</td>
<td>12681.7 (72.51)</td>
<td>36751.3 (13.59)</td>
</tr>
<tr>
<td>CL (mL/hour/kg)</td>
<td>3126.3 (N/A)</td>
<td>5953.1 (7.79)</td>
<td>24676.8 (38.72)</td>
<td>56313 (27.35)</td>
<td>6542.7 (3.21)</td>
<td>25057.7 (N/A)</td>
<td>23770.9 (53.14)</td>
<td>52666.3 (24.27)</td>
</tr>
<tr>
<td>t1/2 (day)</td>
<td>0.3199 (N/A)</td>
<td>0.5074 (7.79)</td>
<td>0.2026 (38.72)</td>
<td>0.1776 (27.35)</td>
<td>0.528 (N/A)</td>
<td>0.195 (N/A)</td>
<td>0.2585 (53.14)</td>
<td>0.1899 (24.265)</td>
</tr>
<tr>
<td>Tmax (hours)</td>
<td>1.580 (N/A)</td>
<td>2.440 (0.98)</td>
<td>1.808 (0.35)</td>
<td>1.637 (0.14)</td>
<td>1.685 (0.09)</td>
<td>1.93 (N/A)</td>
<td>1.562 (0.11)</td>
<td>1.558 (0.06)</td>
</tr>
</tbody>
</table>

NOTE: All values are represented as geometric mean (%CV). Abbreviations: AUC0–21, area under the concentration-time curve from 0 to 21 days; Cmax, maximum concentration; CL, clearance; T1/2, plasma half-life; Tmax, time at which Cmax is observed.

*Only one sample available for analysis.
enrolled on the trial may provide other obstacles to an effective T-cell response (e.g., MDSC, Treg) so that effective immune checkpoint therapy may require combination therapies for maximal impact (25, 32).

Immune-related response criteria had not been developed at the start of trial so standard RECIST criteria were used to determine responses. Analysis revealed that no patients would have been able to remain on therapy after radiologic progression utilizing modified RECIST that takes into account the possibility of delayed responses. Because of the concern that the pediatric tumor types on phase I trials tend to progress at first imaging, patients were imaged at 6 weeks rather than waiting to the end of induction at 12 weeks which had been standard on previous melanoma trials. Indeed the majority of patients were taken off treatment at 6 weeks for progressive disease.

This study provides a foundation for the use of future immune checkpoint inhibitors in children. Algorithms to deal with immune-related toxicities were applied safely to pediatric patients. As with all immunotherapy checkpoint inhibitor trials, management includes education of patient/family and medical care teams to intervene early and appropriately following the onset of immune-related symptoms. Given the toxicities and inability to predict toxicity or response, we do not see a role for single-agent ipilimumab in the pediatric tumors; however, the application of anti-CTLA-4 in combination with other checkpoint inhibitors or immune-modifying agents may hold promise and further pediatric studies are anticipated. Starting ipilimumab doses in combination trials using levels tolerated in adult trials would be supported by the findings of this study.

Disclosure of Potential Conflicts of Interest
C. Rodriguez-Galindo is a consultant/advisory board member for Novimmune. J.D. Wolchok reports receiving a commercial research grant and other research support from and is a consultant/advisory board member for Bristol-Myers Squibb. No potential conflicts of interest were disclosed by the other authors.
Authors’ Contributions

Conception and design: M. Merchant, H. Streicher, C.L. Mackall
Development of methodology: M. Merchant
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M. Merchant, M. Wright, K. Baird, L. Wexler, C. Rodriguez-Calindo, D. Bernstein, C. Delbrook, M. Lodi, B. Rishop, J.D. Wolchok, C.L. Mackall
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M. Merchant, W. Wright, C.L. Mackall
Writing, review, and/or revision of the manuscript: M. Merchant, M. Wright, K. Baird, L. Wexler, C. Rodriguez-Calindo, D. Bernstein, M. Lodi, J.D. Wolchok, G.L. Mackall
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Merchant, D. Bernstein, C. Delbrook

References


Study supervision: M. Merchant, H. Streicher, C.L. Mackall
Other (pediatric endocrinologist managing endocrine-related complications faced by the patients in this trial—associate investigator): M. Lodi

Grant Support

This research was supported in part by the Intramural Research Program of the NIH, NCI.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 2, 2015; revised September 8, 2015; accepted October 14, 2015; published OnlineFirst November 3, 2015.
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

Melinda S. Merchant, Matthew Wright, Kristin Baird, et al.


Updated version
Access the most recent version of this article at:

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2015/11/03/1078-0432.CCR-15-0491.DC1

Cited articles
This article cites 32 articles, 15 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/22/6/1364.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/22/6/1364.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/22/6/1364.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.